2022
Electroencephalographic changes in purified pharmaceutical cannabidiol therapy
Herlopian A, Barnett JR, Nascimento FA, Lee H, Thiele EA. Electroencephalographic changes in purified pharmaceutical cannabidiol therapy. Epilepsy & Behavior 2022, 128: 108558. PMID: 35078115, DOI: 10.1016/j.yebeh.2022.108558.Peer-Reviewed Original ResearchMeSH KeywordsCannabidiolChildDrug Resistant EpilepsyElectroencephalographyHumansPharmaceutical PreparationsRetrospective StudiesConceptsInterictal epileptiform dischargesElectroencephalographic changesCBD treatmentIctal findingsSleep architectureEEG changesInvestigational New Drug programPredominant seizure typeNew drug programPre-treatment EEGYears of ageSubjective cognitive improvementElectrographic findingsElectrographic improvementRefractory epilepsySeizure typesClinical outcomesElectrographic changesEpileptiform dischargesPatientsCognitive improvementDrug programsSubstantial associationEEG studiesTreatment
2020
Cannabidiol in treatment of refractory epileptic spasms: An open-label study
Herlopian A, Hess EJ, Barnett J, Geffrey AL, Pollack SF, Skirvin L, Bruno P, Sourbron J, Thiele EA. Cannabidiol in treatment of refractory epileptic spasms: An open-label study. Epilepsy & Behavior 2020, 106: 106988. PMID: 32169600, DOI: 10.1016/j.yebeh.2020.106988.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnticonvulsantsCannabidiolChildChild, PreschoolDrug Resistant EpilepsyElectroencephalographyFemaleHumansMaleSeizuresTreatment OutcomeConceptsRefractory epileptic spasmsEpileptic spasmsResponder rateAdjunctive therapyCBD treatmentInvestigational new drug trialsOpen-label studyMonths of treatmentSafe adjunctive therapyNew drug trialsInstitutional review boardSubjective reportsBaseline medicationsCBD initiationElectrographic findingsHypsarrhythmia patternClinical responseSeizure frequencyAdverse eventsClinical efficacyElectrographic changesSubjective improvementTarget dosageDrug trialsInitial dosage